Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish pharmaceutical firm Moberg Pharma's partner Menarini Asia-Pacific has received approval to market for its fungal nail product in China.
Subscribe to our email newsletter
Kerasal Nail is a prescription-free, over-the-counter (OTC) drug used to treat nail disease and is sold under the names Kerasal Nail, Naloc/Nalox and Emtrix.
The company said that launch preparations of Kerasal Nail in several markets are progressing ahead of plan.
Moberg’s distribution agreement with the Menarini Group includes Italy, China and eight Southeast Asian countries.
The eight Southeast Asian countries include Singapore, Taiwan, Indonesia, Philippines, Malaysia, Hong Kong, Thailand and Vietnam.
Additionally, Menarini has started launch activities of the product in Malaysia, Singapore and Hong Kong and preparations are ongoing in the other markets in the region.
Moberg Pharma CEO Peter Wolpert said: "We are excited about the progress that Menarini Asia-Pacific has made in registration and launch preparation activities. Kerasal Nail has significant potential in the region.
"Assuming successful launches, the region will be an important contributor to revenues and earnings from 2015 and onwards."
The company’s OTC portfolio includes the brands such as Kerasal, Jointflex, Kerasal Nail, Domeboro, Vanquish and Fergon.